scPharmaceuticals Inc. (SCPH)

4,5400 +0,0700 (+1,57%) Börsenschluss: 04:00PM EDT

scPharmaceuticals Inc.

25 Mall Road
Suite 203
Burlington, MA 01803
United States
617 517 0730
https://www.scpharmaceuticals.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 135

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. John H. Tucker	President, CEO, Principal Executive Officer & Director	981,56k	N/A	1963
Mr. Michael D. Hassman	Senior Vice President of Technical Operations	N/A	N/A	N/A
Katherine Taudvin	Vice President of Corporate Affairs & Human Resources	N/A	N/A	N/A
Steve Parsons	Senior Vice President of Commercial	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Corporate Governance

scPharmaceuticals Inc.s ISS Governance QualityScore, Stand 29. April 2024, lautet 6. Die grundlegenden Scores sind Audit: 2, Vorstand: 5, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.